Hedge fund manager Canary Capital has filed with the U.S. Securities and Exchange Commission to launch an exchange-traded fund tied to Injective’s INJ token, the company disclosed in a filing on Thursday.

Called the Canary Staked INJ ETF, the proposed product would track the price of INJ while also offering staking rewards to investors. Injective is the native token of the Injective blockchain, a layer-1 protocol built for decentralized finance applications.

In a press release, the firm said it has seen “significant and growing demand” from both retail and institutional investors for regulated exposure to Injective. The ETF is designed to lower technical hurdles and promote wider adoption of staking-based crypto investments, according to the form.

Staking allows token holders to lock up their assets to help secure a blockchain network and, in return, earn periodic rewards. These rewards often require self-custody or navigating on-chain interfaces — something the proposed ETF structure would aim to simplify.

This latest filing adds to Canary Capital’s growing list of pending crypto ETFs. The hedge fund is also seeking approval for ETFs tracking Litecoin (LTC), Hedera (HBAR), Sui (SUI), TRON (TRX), XRP (XRP), and the meme-inspired token PENGU (PENGU). None of the products have received regulatory approval.

While the SEC has approved spot bitcoin (BTC) ETFs and more recently spot ether (ETH) ETFs, it has not yet officially approved any ETFs that include staking yields. A Solana (SOL) ETF including staking features launched earlier this month but that fund didn’t require approval from the regulator.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。